Alnylam Pharmaceuticals (ALNY) Stock Forecast & Price Target

Alnylam Pharmaceuticals is forecasted to experience significant growth in the coming years, driven by the successful development and commercialization of a strong pipeline of RNAi therapeutics. The company's strategic partnerships and initiatives, especially in the field of cardiovascular disease, are likely to contribute to this growth. Though potential competition and market risk remain, the analysts project a positive outlook for Alnylam's overall financial performance and profitable hematology franchise. Despite a delay in generic competition, their estimated impact on one of their drugs, the company's price target remains unchanged.

Alnylam Pharmaceuticals is facing potential lower revenue due to increased competition in the ATTR-CM market, with a decrease in projected peak annual revenue for AMVUTTRA from $9.48 billion to $9.55 billion and decreased projected peak annual revenue for nucresiran from $20.57 billion to $22.30 billion. Additionally, they will face increased expenses with a higher price target of $485 due to fine-tuning expense estimates and the opt-out of mivelsiran for co-development by Regeneron, leaving Alnylam with 100% global development and commercialization rights and a competitive market for their other partnered CNS programs. However, Alnylam and Regeneron believe that the differentiated RNAi mechanism of action will remain attractive to physicians and patients, potentially mitigating some of the competitive pressures.